MSN Laboratories Gains CDSCO Approval for Generic Semaglutide in India

MSN Laboratories has received official approval from the Central Drugs Standard Control Organisation for generic semaglutide, reinforcing its regulatory readiness and commitment to bringing advanced metabolic therapies to patients across India. Following this regulatory milestone, the company is targeting a commercial launch of the product in the Indian market by the end of March 2026.

Semaglutide, a leading GLP-1 receptor agonist, is primarily used for the advanced management of type-2 diabetes and has gained global recognition for its efficacy in blood sugar control. The upcoming launch aligns with a broader shift in the Indian market as it prepares for the entry of generic semaglutide, driven by recent regulatory momentum and the expiration of key patents.

MSN Laboratories aims to leverage this timing to expand access to next-generation treatments that were previously restricted by high costs or limited availability. By introducing a high-quality generic alternative, the company seeks to alleviate the growing burden of chronic metabolic conditions on the Indian healthcare system.

The company is focusing on the complex manufacturing of peptide therapies, which require high levels of scientific precision and specialized facilities. This technical capability ensures that the transition from a branded biological to a generic equivalent maintains the strict safety and efficacy standards required by international health authorities.

The rise of diabetes in India necessitates a patient-centric development strategy that prioritizes both quality and accessibility. The goal is to provide a reliable supply chain that can meet the massive domestic demand while also serving international markets in the future.

Established in 2003, MSN Laboratories has grown into one of the fastest-growing research-oriented pharmaceutical groups globally, with a footprint spanning over 100 countries. The company operates 25 modern manufacturing facilities across India and the USA, including 17 dedicated to active pharmaceutical ingredients and six for finished dosage forms.

The company's R&D centre has filed over 1,000 national and international patents and more than 200 ANDA applications. MSN currently holds the top global position in active Drug Master File registrations in the USA, a testament to its commitment to transparency and high-grade chemical manufacturing. With a portfolio of over 500 APIs and 400 finished dosage forms, the group already serves more than 50 million patients worldwide across 35 therapeutic areas.

As the March 2026 launch date approaches, MSN Laboratories continues to reinforce its commitment to supply chain resilience and healthcare affordability. By integrating scientific excellence with large-scale manufacturing, the group is positioned to become a dominant player in the GLP-1 market.